Sumitomo Pharma raised its full-year net profit forecast to ¥94 billion and indicated that it plans to resume its year-end dividend at ¥15. Growth in its flagship drug in the U.S. market is believed to have contributed.
Sumitomo Pharma raised its full-year net profit forecast to ¥94 billion. Under the new outlook, sales of its flagship drug in the U.S. are expected to grow, contributing to an improvement in overall performance.
The company also announced plans to resume its year-end dividend at ¥15. The resumption of dividends is positioned as part of the company’s capital allocation policy.